{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:18:38Z","timestamp":1769606318484,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.nmd.2014.08.006","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T07:32:20Z","timestamp":1410334340000},"page":"70-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of intravenous immunoglobulin for treatment of Lambert\u2013Eaton myasthenic syndrome without anti-presynaptic P\/Q-type voltage-gated calcium channel antibodies: A case report"],"prefix":"10.1016","volume":"25","author":[{"given":"Akinori","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatu","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2014.08.006_bib0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome. A review of 50 cases","volume":"111","author":"O'Neill","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2014.08.006_bib0015","first-page":"1237","article-title":"The Lambert-Eaton myasthenic syndrome: a study of 110 Japanese cases","volume":"39","author":"Motomura","year":"1999","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.nmd.2014.08.006_bib0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(81)90474-8","article-title":"Autoimmune etiology for myasthenic (Eaton-Lambert) syndrome","volume":"2","author":"Lang","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2014.08.006_bib0025","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mus.1140","volume":"24","author":"AAEM Quality Assurance Committee","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2014.08.006_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","article-title":"An improved diagnostic assay for Lambert-Eaton myasthenic syndrome","volume":"58","author":"Motomura","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2014.08.006_bib0035","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","article-title":"Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma","volume":"40","author":"Chalk","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.08.006_bib0040","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2014.08.006_bib0045","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1749-6632.1998.tb11023.x","article-title":"A treatment algorithm for Lambert-Eaton myasthenic syndrome","volume":"841","author":"Newsom-Davis","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2014.08.006_bib0050","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1749-6632.1998.tb11024.x","article-title":"Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients","volume":"841","author":"Tim","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2014.08.006_bib0055","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.08.006_bib0060","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/WNL.42.7.1422","article-title":"Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy","volume":"42","author":"Bird","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.08.006_bib0065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.20269","article-title":"Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins","volume":"31","author":"Buchwald","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2014.08.006_bib0070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<674::AID-MUS3>3.0.CO;2-5","article-title":"Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin","volume":"20","author":"Muchnik","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2014.08.006_bib0075","first-page":"682","article-title":"Use of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome","volume":"102","author":"Peterlin","year":"2002","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.nmd.2014.08.006_bib0080","first-page":"745","article-title":"Lambert-Eaton myasthenic syndrome","volume":"63","author":"Motomura","year":"2011","journal-title":"Brain Nerve"},{"key":"10.1016\/j.nmd.2014.08.006_bib0085","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","article-title":"Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients","volume":"59","author":"Nakao","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.08.006_bib0090","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/jnnp.2004.048140","article-title":"Age associated axonal features in HNPP with 17p11.2 deletion in Japan","volume":"76","author":"Koike","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2014.08.006_bib0095","unstructured":"Richard J., Barohn M.D.. The Quantitative Myasthenia Gravis (QMG) Test: the manual. Myasthenia Gravis Foundation of America, Inc. 2000."},{"key":"10.1016\/j.nmd.2014.08.006_bib0100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/mus.20672","article-title":"Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome","volume":"35","author":"Oh","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2014.08.006_bib0105","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.WNL.0000041026.90947.79","article-title":"What's in the serum of seronegative MG and LEMS?: MuSK et\u00a0al","volume":"59","author":"Abicht","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.08.006_bib0110","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/317737a0","article-title":"Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line","volume":"317","author":"Roberts","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2014.08.006_bib0115","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1046\/j.1471-4159.1995.64041696.x","article-title":"Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenic syndrome","volume":"64","author":"el Far","year":"1995","journal-title":"J Neurochem"},{"key":"10.1016\/j.nmd.2014.08.006_bib0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneuroim.2008.04.001","article-title":"Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome","volume":"197","author":"Martin-Moutot","year":"2008","journal-title":"J Neuroimmunol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896614006348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896614006348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:03:32Z","timestamp":1760774612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896614006348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0960896614006348"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2014.08.006","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of intravenous immunoglobulin for treatment of Lambert\u2013Eaton myasthenic syndrome without anti-presynaptic P\/Q-type voltage-gated calcium channel antibodies: A case report","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2014.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}